Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Patient, Caregiver, and Healthcare Professional Perspectives on Seizure Freedom, Seizure Control, and Treatment Goals
Epilepsy/Clinical Neurophysiology (EEG)
P14 - Poster Session 14 (8:00 AM-9:00 AM)
12-005
Evaluate how adults living with epilepsy, caregivers, and healthcare professionals (HCPs) view seizure freedom, seizure control, and treatment goals.
Patients, caregivers, and HCPs may have discordant perceptions about whether or not seizure freedom is a reasonable goal, the definitions of seizure control, and treatment goals that are important to patients.
An online survey of 400 adult patients with epilepsy, 201 caregivers, and 258 HCPs was conducted by Kantar Health in 2019. The 10-part survey included questions about seizure freedom, definitions of control, and treatment goals.
29% of patients and 37% of caregivers said they had heard or seen the term seizure freedom whereas 65% of HCPs reported using that term with patients and caregivers. When seizure freedom was defined as 0 seizures in the past 12 months, 61% of patients and 45% of HCPs thought it was always a reasonable goal. HCPs reported that 46%-52% of their patients were seizure-free. Only 13% of sampled patients had 0 seizures in the last year. Physicians reported treating an average of 72 patients with focal- or partial-onset seizures; of these, 47% were seizure-free, 33% were “in control,” and 20% were uncontrolled. Of those “in control,” 63% reported 1-12 seizures/yr, 22% reported 13-24 seizures/yr, 10% reported 25-48 seizures/yr, and 5% reported >48 seizures/yr. When patients were asked how many seizures/yr would be considered “in control,” mean response was 3.6 seizures/yr. Treatment goals reported as being extremely important by ≥60% of patients included finding a treatment that works (68%), having fewer seizures (67%), no longer having big seizures (64%), being able to feel in control (64%), having seizure freedom (62%), and being able to live independently (60%).
The results of this survey suggest there may be an opportunity for patients and HCPs to work more closely to align on individualized treatment goals.
Authors/Disclosures
Danielle A. Becker, MD
PRESENTER 		Dr. Becker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis, Inc. Dr. Becker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sk life Science. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus Pharmaceuticals. Dr. Becker has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurelis, Inc. Dr. Becker has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sk Life Science. Dr. Becker has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Jazz pharmaceuticals. Dr. Becker has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UBC. Dr. Becker has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for LivaNova. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neuropace. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Supernus Pharmaceuticals.
Lucretia Long, DNP, APRN-CNP, FAES (Ohio State University, Wexner Medical Center) Mrs. Long has received personal compensation for serving as an employee of SKLife. Mrs. Long has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis. Mrs. Long has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SKLife. Mrs. Long has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Mrs. Long has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst Pharmaceutical. Mrs. Long has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Liva Nova. Mrs. Long has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurelis. Mrs. Long has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK lIFE. Mrs. Long has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Liva Nova.
Nancy Santilli, RN, PNP, MN No disclosure on file
No disclosure on file
No disclosure on file